For secondary outcomes, risks were higher for acute pancreatitis (HR 1.054, 95% CI 1.014–1.096), with no significant difference in chronic pancreatitis (HR 1.166, 95% CI 0.970–1.240) and pancreatic cancer (HR 0.981, 95% CI 0.912–1.055) compared to SGLT2 inhibitor Users (Supplementary Table 5). Here, SLC5A2 is linked to pancreatic neoplasm.